Table 3. Comparison of various clinical factors between the 10 and 40 mg groups before and after treatment.
| Factor | Before | After | ||||
|---|---|---|---|---|---|---|
| 10 mg | 40 mg | P valuea | 10 mg | 40 mg | P valuea | |
| CPK, U/L | 113.8±94.0 | 104.0±43.7 | 0.765 | 131.9±136.0 | 96.5±46.4 | 0.368 |
| AST, IU/L | 22.7±16.0 | 21.4±9.3 | 0.632 | 24.2±14.9 | 21.8±8.4 | 0.984 |
| ALT, IU/L | 25.9±19.9 | 27.0±17.0 | 0.447 | 26.8±16.6 | 27.4±14.8 | 0.572 |
| Insulin, µIU/mL | 13.6±11.5 | 21.6±45.6 | 0.624 | 10.8±8.3 | 14.3±15.3 | 0.408 |
| C-peptide, pmol/mL | 1.1±0.7 | 1.2±1.1 | 0.794 | 0.9±0.5 | 1.0±0.6 | 0.763 |
| HbA1c, % | 7.6±1.6 | 7.3±1.8 | 0.267 | 7.3±1.2 | 7.2±1.4 | 0.606 |
| Glucose, mg/dL | 158.9±53.0 | 167.9±75.0 | 0.640 | 154.2±62.0 | 144.0±49.0 | 0.540 |
| TC, mg/dL | 209.1±30.0 | 211.0±22.8 | 0.654 | 148.2±24.1 | 132.3±26.2 | 0.023 |
| LDL-C, mg/dL | 138.6±23.9 | 139.5±24.2 | 0.992 | 82.7±18.8 | 68.0±22.7 | 0.006 |
| HDL-C, mg/dL | 48.7±12.3 | 46.7±10.6 | 0.559 | 47.3±10.7 | 47.6±11.8 | 0.907 |
| TG, mg/dL | 181.3±93.1 | 191.3±117.4 | 0.968 | 133.7±75.9 | 129.8±62.6 | 0.876 |
| GDF-15, pg/mL | 1,460.6±874.8 | 1,271.6±801.0 | 0.280 | 1,451.0±770.8 | 1,341.4±855.2 | 0.376 |
| HOMA-IR | 5.1±4.0 | 6.5±9.6 | 0.984 | 4.2±4.8 | 4.9±4.7 | 0.355 |
| hsCRP, mg/dL | 2.6±2.7 | 2.3±2.6 | 0.486 | 1.3±1.1 | 1.0±0.7 | 0.989 |
Values are presented as mean±standard deviation.
CPK, creatine phosphokinase; AST, aspartate transaminase; ALT, alanine transaminase; HbA1c, glycosylated hemoglobin; TC, total cholesterol; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; TG, triglyceride; GDF-15, growth differentiation factor 15; HOMA-IR, homeostasis model assessment-estimated insulin resistance; hsCRP, high-sensitivity C-reactive protein.
aP value determined using the Mann-Whitney U test.